MDA 2026 Sysnav Healthcare

Sysnav Healthcare at MDA 2026

Sysnav Healthcare is excited to announce our participation in the 2026 MDA Clinical & Scientific Conference, organized by the Muscular Dystrophy Association, taking place in Orlando, Florida.

From March 8 to 11, our team was on-site to share how digital health technology is transforming the way we measure disease progression and patient mobility in real-world settings.

This year, three posters showcased the latest real-world data generated with Syde®, our wearable digital endpoint platform, across several neuromuscular diseases:

  • DMD (under 4 years old) — Poster #26S “SV95C is a Robust Functional Motor Measure for Ambulant DMD Below 4 Years Old” Presented by Laurent Servais from the University of Liège and University of Oxford. Download the DMD poster here.
  • ALS — Poster #190M “Wearable Sensor-Derived Digital Outcomes for Quantifying Gait in ALS” In collaboration with James Berry’s team at Massachusetts General Hospital. Download the ALS poster here.
  • FSHD — Poster #315T “Evaluation of Ambulatory Function in Daily Life with an Ankle Wearable Sensor in Ambulant Patients with FSHD” In collaboration with John Vissing and Nicolai Preisler’s teams at the Copenhagen Neuromuscular Center and Research Unit. Download the FSHD poster here.

 

We are grateful to the Muscular Dystrophy Association for bringing together the global clinical and scientific community.

More To Explore

Sysnav Healthcare at ICNMD 2026
Events

Sysnav Healthcare at ICNMD 2026

How do you assess a patient too young to follow instructions? That’s the challenge our Program Director, Damien Eggenspieler, tackled on the ground at ICNMD

Sysnav Healthcare at EAN
Events

Sysnav Healthcare at EAN 2026

Can a single wearable platform derive meaningful clinical conclusions across 10+ neurological diseases? The evidence says yes.We’re presenting three new posters at EAN 2025, each

Sysnav Healthcare is participating in ENCALS 2026
Events

Sysnav Healthcare at ENCALS 2026

As the development of innovative therapies for ALS accelerates around the world, the need for objective and clinically meaningful measures of disease progression has never